Barclays reaffirmed their overweight rating on shares of Microsoft (NASDAQ:MSFT) in a research report sent to investors on Friday morning. Barclays currently has a $117.00 target price on the software giant’s stock, up from their previous target price of $108.00.
Procter & Gamble Co. (NYSE: PG) posted a share price loss of 1.3% last week, not much, but enough to maintain its rank as the worst-performing Dow Jones industrialaverage stock of the year to date. So far in 2018, the shares have lost 20.8%.
The second-worst Dow stock so far this year is General Electric Co. (NYSE: GE), which is down 17.6%. That is followed by 3M Co. (NYSE: MMM), down....More>>>
Five years ago, Warren Buffett touted his ‘big four’ stock bets when building a $10.7 billion stake in IBM, a massive holding to go with Berkshire Hathaway’s long-term investments in American Express, Coca-Cola and Wells Fargo. Now, after buying 120 million shares of Apple over the past year, Berkshire Hathaway has a position in the iPhone-maker worth $18 billion....More>>>
The news hit the wire that business software company Deltek is being acquired by Roper Technologies (NYSE:ROP). Taken private by Thoma Bravo in a deal that closed in 2012, Deltek managed to continue its growth, acquire several new products for its portfolio of software focused on project-based businesses, and set an aggressive path to reinvent itself as a modern cloud services provider. According....More>>>
Ipswich, MA, based Investment company Ipswich Investment Management Co., Inc. buys Yahoo!, Adobe Systems, SPDR Dow Jones Industrial Average, State Street, iShares Core S&P Mid-Cap, sells Palo Alto Networks, SCANA, Target, Edwards Lifesciences, FireEye during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Ipswich Investment Management Co., Inc......More>>>
I believe that 2017 will turn out to be a break-out year for Exxon Mobil (NYSE:XOM) as a combination of higher oil pricing and an increase in low-cost production will help the company deliver strong revenue growth. More importantly, as Exxon ramps up its production from its low-cost assets, it will witness a rise in its bottom line performance over the long run. As a result, investors can expect....More>>>
Related NEFF Wall Street's M&A Chatter From August 17: United Rentals-Neff, Hormel Foods-Fontanini, Blackstone-Harvest Fund United Rentals' New Acquisition, Explained Related TEVA No Pain, No Gain: How The American Military Wants Big Pharma To Cure The Opioid Crisis Watch These 7 Huge Put Purchases In Thursday....More>>>
Vical (NASDAQ:VICL) has been a horror show for investors. Failed trials, poor technology and a lack of awareness have left this small biotech company from San Diego all but forgotten. There are many reasons that a long-term investor would have no interest in this company even though it passes Benjamin Graham’s criteria as a net-net investment because it is trading below cash. I believe there....More>>>
Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon....More>>>
Tianjin Tasly Pharma (SHA: 600535) is in talks to IPO its biopharma division in Hong Kong later this year with the goal of raising $1 billion. If it happens, the IPO will probably be Hong Kong's largest biopharma IPO this year. Tasly, known for its TCM offerings, has been act
Corporacion America (NYSE: CAAP) and Grupo Aeroportuario Centro Norte (NASDAQ:OMAB) are both small-cap transportation companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analys
Franco-Nevada Corporation (NYSE:FNV) is a gold streaming company that operates in the niche precious metals industry, which includes fellow giants Wheaton Precious Metals (NYSE:WPM) and Royal Gold, Inc. (NASDAQ:RGLD). While it's the youngest of this gold and silver streaming stock trio, it's als
Wall Street brokerages predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report ($0.15) earnings per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Neurocrine Biosciences’ earnings, with the highest EPS estimate coming